Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EV-Checklist: AI-Powered Rapid Documentation for Enhancing Transparency and Accessibility of Extracellular Vesicle Research Data.

Journal of extracellular vesicles·2026
Same author

Development of Potency Assays for Therapeutic EVs: The Art of Congruence.

Journal of extracellular vesicles·2026
Same author

Current Perspective on Human Milk Derived Vesicles and Their Potential Therapeutic Use: A Scoping Review.

Journal of extracellular vesicles·2026
Same author

Corrigendum to "Exploring the role of extracellular vesicles in otorhinolaryngology: From diagnostics to therapeutic potential" [Int. J. Pharm. 692 (2026) 126634].

International journal of pharmaceutics·2026
Same author

Red Blood Cell Depletion in Patients With Hyperferritinemia: Comparison of Two Apheresis Systems.

Journal of clinical apheresis·2026
Same author

Deep immune-phenotyping of HLA-homozygous iPS-cardiomyocytes by spectral flow cytometry.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 13, 2026

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications
10:30

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Published on: December 8, 2016

Two steps to functional mesenchymal stromal cells for clinical application.

Christina Bartmann1, Eva Rohde, Katharina Schallmoser

  • 1Department of Internal Medicine, Division of Hematology and Stem Cell Transplantation, Medical University, Auenbrugger Platz 38, A-8036 Graz, Austria.

Transfusion
|July 28, 2007
PubMed
Summary

A new two-step method efficiently expands multipotent mesenchymal stromal cells (MSCs) for clinical trials. This technique yields over 1.5 x 10^8 MSCs from small marrow volumes within four weeks, enabling broader therapeutic testing.

More Related Videos

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions
11:05

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions

Published on: March 18, 2017

Related Experiment Videos

Last Updated: Jul 13, 2026

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications
10:30

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Published on: December 8, 2016

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions
11:05

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions

Published on: March 18, 2017

Area of Science:

  • Cell Biology
  • Regenerative Medicine
  • Biotechnology

Background:

  • Ex vivo expansion of multipotent mesenchymal stromal cells (MSCs) is crucial for clinical trials.
  • Current methods often fail to produce sufficient MSCs (2 x 10^6/kg) for adult patients.
  • A novel two-step procedure aims to overcome these limitations.

Purpose of the Study:

  • To develop an efficient method for large-scale MSC propagation.
  • To determine the optimal seeding density for MSC expansion.
  • To evaluate the phenotype and immunomodulatory function of expanded MSCs.

Main Methods:

  • A two-step culture procedure was employed.
  • Variable MSC seeding densities (2.5–2500/cm²) were tested.
  • MSC phenotype, differentiation potential, and immunomodulatory function were assessed.

Main Results:

  • Reduced seeding density significantly enhanced MSC propagation.
  • Low-density expanded MSCs maintained their characteristic phenotype (CD29+, CD73+, CD90+, CD105+) and differentiation capacity.
  • The procedure yielded 1.5–3.7 x 10^8 functional MSCs within 13–15 days of secondary expansion.

Conclusions:

  • A two-step protocol using minimal marrow aspirates (10 mL) can consistently generate over 1.5 x 10^8 MSCs in under four weeks.
  • This efficient clinical-scale MSC propagation method supports the rational testing of MSC-based therapies.
  • Optimized low-density seeding is key to successful MSC expansion.